Mechanisms of disease: The impact of antithrombotic therapy in cancer patients

Nature Clinical Practice Oncology

Volumn 2, Issue 7, 2005, Pages 356-363

  Petralia, Gloria A ^a   Lemoine, Nick R ^a   Kakkar, Ajay K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Coagulation proteases; Low molecular weight heparins; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; CORTISONE; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROCOAGULANT; SERINE PROTEINASE; SODIUM CHLORIDE; THROMBOPLASTIN; WARFARIN; FIBRINOLYTIC AGENT; PEPTIDE HYDROLASE;

BLOOD CLOTTING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HYPERCOAGULABILITY; LUNG SMALL CELL CANCER; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; VENOUS THROMBOEMBOLISM; DOWN REGULATION; DRUG EFFECT; NEOPLASM; PHYSIOLOGY; SURVIVAL; THROMBOEMBOLISM;

BLOOD COAGULATION; CLINICAL TRIALS; DOWN-REGULATION; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; PEPTIDE HYDROLASES; PHENOTYPE; SURVIVAL ANALYSIS; THROMBOEMBOLISM;

EID: 23844481864     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0225     Document Type: Review

References (51)

1. Trousseau A (1865) Phlegmasia alba dolens. In Clinique Medicale de l'Hotel Dieu de Paris edn 2 (3 vols) 654-712 Paris: Ballière
2. Geerts WH et al. (2004) Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): 338S-400S
3. Buller HR et al. (2004) Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl): 401S-428S
4. Prandoni P et al. (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100: 3484-3488
5. Lee AY (2005) Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol 128: 291-302
6. Kakkar AK et al. (1995) Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 346: 1004-1005
7. Dahlback B (2000) Blood coagulation. Lancet 355: 1627-1632
8. Virchow R (1856) Collected essays on scientific medicine. (Gesammelte abhandlungen zur wissenschaftlichen medizin) 219-732 Frankfurt: Meidinger
9. Ott I et al. (1998) A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 140: 1241-1253
10. Kakkar AK et al. (1995) Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82: 1101-1104
11. Rickles FR et al. (1995) Tissue factor expression in human leukocytes and tumor cells. Thromb Haemost 74: 391-395
12. Tallman MS and Kwaan HC (1992) Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79: 543-553
13. Donati MB et al. (1986) Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 46: 6471-6474
14. Kakkar AK et al. (1999) Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg 86: 890-894
15. Zhang Y et al. (1994) Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94: 1320-1327
16. Contrino J et al. (1996) In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 2: 209-215
17. Poon RT et al. (2003) Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9: 5339-5345
18. Dorfleutner A et al. (2004) Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 15: 4416-4425
19. Carmeliet P et al. (1995) Role of tissue factor in embryonic blood vessel development. Nature 383: 73-75
20. Belting M et al. (2004) Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nature Med 10: 502-509
21. Beerepoot LV et al. (2004) Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett 213: 241-248
22. Rickles FR et al. (2001) The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: Tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 72: 145-150
23. Shweiki D et al. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845
24. Poon RT et al. (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207-1225
25. Mohle R et al. (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94: 663-668
26. Wang X et al. (2004) Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 112: 994-1002
27. Versteeg HH et al. (2004) Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene 23: 410-417
28. Yu JL et al. (2005) Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 105: 1734-1741
29. Even-Ram S et al. (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med 4: 909-914
30. Levine MN et al. (2003) From Trousseau to targeted therapy: New insights and innovations in thrombosis and cancer. J Thromb Haemost 1: 1456-1463
31. Taniguchi T et al. (1998) Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 58: 4461-4467
32. Wojtukiewicz MZ et al. (2001) Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 86: 1416-1420
33. Caunt M et al. (2003) Thrombin induces neoangiogenasis in the chick chorioallantoic membrane. J Thromb Haemost 1: 2097-2102
34. Zacharski LR et al. (1984) Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53: 2046-2052
35. Lebeau B et al. (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74: 38-45
36. Gould MK et al. (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800-809
37. Kakkar AK et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22: 1944-1948
38. Lee AY et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153
39. Lee AY et al. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of outpatients with cancer and venous thromboembolism. J Clin Oncol 23: 2123-2129
40. Altinbas M et al. (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2: 1266-1271
41. Klerk CP et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135
42. Smorenburg SM and Van Noorden CJ (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53: 93-105
43. Vlodavsky I et al. (1999) Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nature Med 5: 793-802
44. Borsig L et al. (2001) Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98: 3352-3357
45. Yoshitomi Y et al. (2004) Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett 207: 165-174
46. Da Silva MS et al. (2003) Heparin modulates integrin-mediated cellular adhesion: Specificity of interactions with alpha and beta integrin subunits. Cell Commun Adhes 10: 59-67
47. Mousa SA and Mohamed S (2004) Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy. Oncol Rep 12: 683-688
48. Mousa SA and Mohamed S (2004) Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92: 627-633
49. Folkman J et al. (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221: 719-725
50. Nasir FA et al. (2003) The low molecular weight heparin dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumour model. Blood 102: [Abstract #2993]
51. Samoszuk M et al. (2003) Inhibition of thrombosis in melanoma allografts in mice by endogenous mast cell heparin. Thromb Haemost 90: 351-360